checkAd

Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer's Disease

FN Media Group Presents Microsmallcap.com Market Commentary

NEW YORK, Oct. 5, 2022 /PRNewswire/ -- A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer's disease, announcing recently that it has gotten approval from Argentina's regulators to begin a Phase ll clinical study using the Company's unique psychedelic molecule, BMND08. Biomind Labs is a biotech research and development company looking into new medicines and nanotech delivery systems for a wide range of psychiatric and neurological diseases. The trial looks at whether BMND08, a treatment based on the natural psychedelic chemical 5-Methoxy-N,N-dimethyltryptamine (also known as 5-MeO-DMT or simply DMT), helps treat the depression and anxiety that are typical in Alzheimer's patients. The Phase ll clinical trial will take place in Argentina, where regulators approved the investigation in May. Although some research has looked into cannabis as a possible cure for Alzheimer's disease symptoms, Biomind's study is thought to be the first to explore a psychedelic like DMT. Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF), Seelos Therapeutics (NASDAQ:SEEL), Takeda Pharmaceuticals (NYSE:TAK), ATAI Life Sciences (NASDAQ:ATAI), and Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) are other companies developing psychedelic-based treatments.

Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a homegrown Canadian company producing natural, scalable and accessible psychedelic and functional mushrooms and synthetic formulations for transformational human experiences.

On September 22, Optimi Health announced that in conjunction with ATMA Journey Centers, the companies have confirmed their intention to proceed with a Phase I clinical trial application (CTA) which will document the safety of Optimi's natural psilocybin biomass and 3,4-methylenedioxy-methamphetamine (MDMA) in healthy patients.

It would be the first experiment approved by Health Canada to evaluate safety and extra markers, such as the mystical experience questionnaire, in healthy participants who have used MDMA.

According to Optimi CEO Bill Ciprick, the purpose of the clinical experiment is to collect data for Optimi's patented formulation using natural EU-GMP psilocybin and MDMA, such as blood pressure, temperature, heart rate, and ECG measurements. These goods are manufactured and tested in-house at Optimi's 20,000-square-foot Princeton, British Columbia facility. Ciprick said that the clinical confirmation of their solutions on healthy patients moves them one step closer to commercialization.

Seite 1 von 5


Nachrichtenquelle: PR Newswire (engl.)
 |  177   |   |   

Schreibe Deinen Kommentar

Disclaimer

Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer's Disease FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Oct. 5, 2022 /PRNewswire/ - A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer's disease, announcing recently that it has gotten approval from …

Nachrichten des Autors

148 Leser
91 Leser
87 Leser
82 Leser
79 Leser
78 Leser
78 Leser
74 Leser
74 Leser
74 Leser
190 Leser
153 Leser
148 Leser
145 Leser
128 Leser
119 Leser
117 Leser
117 Leser
116 Leser
116 Leser
1064 Leser
1032 Leser
1007 Leser
429 Leser
417 Leser
334 Leser
301 Leser
296 Leser
239 Leser
232 Leser
9496 Leser
1870 Leser
1722 Leser
1183 Leser
1064 Leser
1032 Leser
1007 Leser
922 Leser
920 Leser
912 Leser